Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

U.S. Alzheimer’s funding increase signed into law

A $122 million boon for U.S. Alzheimer’s research funding was signed by President Obama on Jan. 16.

PET study tests how a video game points out possible Alzheimer’s disease

Akili Interactive Labs and Pfizer are partnering to evaluate patients’ risk of developing Alzheimer’s disease by following their performance while playing a specialized video game, Akili announced Jan. 9.

Thumbnail

Tau therapeutic agent in the works

Biopharmaceutical company Intellect Neurosciences announced Jan. 16 that a potentially disease-modifying tau agent is in the preliminary stages of validation for neurological diseases including Alzheimer’s.

Thumbnail

Congress presents plea for $122M Alzheimer’s disease funding

A bill that would increase Alzheimer’s research funding appropriations by $122 million has passed Congress and is now under deliberation by the president.

Helmholtz Zentrum Munchen produces three new spin-offs

German research center Helmholtz Zentrum Munchen announced today that the company had successfully finalized three new spin-offs within the past year to include SurgVision, Trianta Immunotherapies and Dosimetrics.

'3D nanoSIMS' molecular imaging system touts nano resolutions

A new label-free molecular imaging system called the 3D nanoSIMS could provide superior drug research studies at intensely tiny spatial resolutions, announced the National Physical Laboratory in Middlesex, United Kingdom, on Dec. 10.

Benzamide imaging agent could lead to a novel therapy for metastatic melanoma

Average survival for metastatic melanoma patients is less than 5 percent after five years—a disheartening figure, but an investigational agent incorporating benzamide in a melanin-targeted SPECT radiotracer could change the numbers, according to a study published Nov. 16 in the Journal of Nuclear Medicine.

Take heart: PET market to increase with new cardiac agents

Two novel cardiovascular PET agents are in the wings from FluoroPharma Medical, according to a recent profile in Forbes magazine.